51,736 results match your criteria Psoriasis


Cytotoxicity of Saikosaponin A targets HEKa cell through apoptosis induction by ROS accumulation and inflammation suppression via NF-κB pathway.

Int Immunopharmacol 2020 Jul 4;86:106751. Epub 2020 Jul 4.

Dermatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, Shaanxi 710004, China. Electronic address:

Saikosaponin A (SSA) is a triterpenoid saponin extracted from oriental medicinal plant Radix bupleuri, possessing various biological functions such as anti-inflammatory, immune regulation and anti-virus. This study aimed to explore therapeutic effects of SSA on psoriasis in both vitro and vivo. Our results showed that SSA increased reactive oxygen species (ROS) generation, and decreased mitochondrial membrane potential (MMP) and M5-induced inflammatory cytokines levels in HEKa cells in a dose-dependent manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2020.106751DOI Listing

Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients.

J Dermatol 2020 Jul 6. Epub 2020 Jul 6.

Department of Dermatology, Venereology and Allergology, University Medical Center, Göttingen, Germany.

Acrodermatitis continua of Hallopeau (ACH) is a rare chronic inflammatory skin disease. Treatment is extremely challenging and mostly based on empirics as there is only scarce evidence from case reports and few small case series. In this retrospective study, patients with ACH treated at five university medical centers were analyzed according to patient and disease characteristics and treatment experience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15466DOI Listing

Autoantibody Production in Obesity: Is There Evidence for a Link Between Obesity and Autoimmunity?

Curr Obes Rep 2020 Jul 6. Epub 2020 Jul 6.

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, Goudi, 11527, Athens, Greece.

Purpose Of Review: During the last decades, obesity and autoimmune disorders have shown a parallel significant rise in industrialized countries. This review aims at providing a comprehensive update of the relationship between the adipose tissue in obesity and autoimmune disorders, highlighting the underlying mechanisms with a particular emphasis on adipokines and pro-inflammatory cytokines, the impaired B cell activity, and the production of natural and pathogenic autoantibody repertoire in the context of obesity.

Recent Findings: Obesity is related to a higher risk of rheumatoid arthritis, psoriasis and psoriatic arthritis, multiple sclerosis, and Hashimoto's thyroiditis, while it may promote inflammatory bowel disorders and type 1 diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13679-020-00397-8DOI Listing

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.

Authors:
Hannah A Blair

Drugs 2020 Jul 6. Epub 2020 Jul 6.

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Risankizumab (Skyrizi; risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (in the EU), those who are candidates for systemic therapy or phototherapy (in the USA) and those who have an inadequate response to conventional therapies (in Japan). In pivotal phase III trials (UltIMMa-1, UltIMMa-2, IMMvent and IMMhance), risankizumab was more effective than placebo, ustekinumab and adalimumab with regard to the proportion of patients achieving ≥ 90% improvement from baseline in Psoriasis Area and Severity Index score (PASI 90) and a static Physician's Global Assessment score of 0 or 1 at week 16, with these benefits maintained over the longer term. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-020-01357-1DOI Listing

Elevated IL-22 in psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL/Bax.

Apoptosis 2020 Jul 6. Epub 2020 Jul 6.

Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

IL-22 is known to mediate inflammation in psoriasis, while IL-22 binding protein (IL-22BP) binds IL-22 to suppress IL-22 signaling. However, the function of IL-22 in regulating apoptosis in psoriasis remains poorly understood. In this study, we found that IL-22/IL-22R1 in lesional skin and IL-22 in serum from psoriatic patients were highly upregulated compared with healthy controls, while IL-22BP was not changed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10495-020-01623-3DOI Listing

[Hypokalemia with pseudo-hyperaldosteronism: Is it Lidl® syndrome?]

Nephrol Ther 2020 Jul 3. Epub 2020 Jul 3.

Division of nephrology, Rennes University Hospital, 2, rue Henri-Le-Guilloux, 35000 Rennes, France; Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR 1085, 9, avenue du Professeur-Léon-Bernard, 35000 Rennes, France.

Introduction: Intoxication induced by glycyrrhizin is a common cause of hypokalaemia by pseudo-hyperaldosteronism.

Observation: We hereby present the observation of a 68-year old patient hospitalised following a full hip-prosthesis operation after a deep hypokalaemia at 2.5mM was observed, with ECG signs (flat T waves and appearance of U waves). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nephro.2020.03.008DOI Listing

Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.

Bioorg Med Chem Lett 2020 Aug 1;30(16):127298. Epub 2020 Jun 1.

Open Innovation, Research & Development, Pharmaceuticals, Bayer AG, D-13353 Berlin, Germany.

We report on the discovery of the new clinical candidate BAY 1003803 as glucocorticoid receptor agonist for the topical treatment of psoriasis or severe atopic dermatitis. In the course of optimizing the amino alcohol series as a highly potent new non-steroidal lead structure, considerations were made as to how physicochemical properties and safety concerns relate to structural motifs. BAY 1003803 demonstrates strong anti-inflammatory activity in vitro paired with a pharmacokinetic profile suitable for topical application. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2020.127298DOI Listing

Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin.

J Allergy Clin Immunol 2020 Jul;146(1):8-16

Division of Dermatology and Venereology, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Unit of Dermatology, Karolinska University Hospital, Department of Dermatology and Venereology, Stockholm, Sweden; Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany. Electronic address:

Autoimmune diseases are driven by either T cells or antibodies reacting specifically to 1 or more self-antigens. Although a number of self-antigens associated with skin diseases have been identified, the causative antigen(s) remains unknown in the great majority of skin diseases suspected to be autoimmune driven. Model diseases such as pemphigus, dermatitis herpetiformis, and more recently psoriasis have added greatly to our understanding of skin autoimmunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2020.05.009DOI Listing

Sphingosine Kinases are Involved in Macrophage NLRP3 Inflammasome Transcriptional Induction.

Int J Mol Sci 2020 Jul 2;21(13). Epub 2020 Jul 2.

Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany.

Recent studies suggested an important contribution of sphingosine-1-phospate (S1P) signaling via its specific receptors (S1PRs) in the production of pro-inflammatory mediators such as Interleukin (IL)-1β in cancer and inflammation. In an inflammation-driven cancer setting, we previously reported that myeloid S1PR1 signaling induces IL-1β production by enhancing NLRP3 (NOD-, LRR- and Pyrin Domain-Containing Protein 3) inflammasome activity. However, the autocrine role of S1P and enzymes acting on the S1P rheostat in myeloid cells are unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21134733DOI Listing

Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement.

Cells 2020 Jul 2;9(7). Epub 2020 Jul 2.

Dermatology Department, Instituto de Investigación Sanitaria Hospital Universitario de la Princesa (IISP), 28006 Madrid, Spain.

miRNAs have been associated with psoriasis since just over a decade. However, we are far from a complete understanding of their role during the development of this disease. Our objective was to characterize the cutaneous expression of miRNAs not previously described in psoriasis, the changes induced following the treatment with biologicals and their association with disease improvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9071603DOI Listing

An optimized biotechnological system for the production of centellosides based on elicitation and bioconversion of cell cultures.

Eng Life Sci 2017 Apr 17;17(4):413-419. Epub 2016 Nov 17.

Laboratori de Fisiologia Vegetal. Facultat de Farmacia Universitat de Barcelona Barcelona Spain.

is a herbaceous plant of Asian traditional medicine. Besides wound healing, this plant is recommended for the treatment or care of various skin conditions such as dry skin, leprosy, varicose ulcers, eczema, and/or psoriasis. Triterpene saponins, known as centellosides, are the main metabolites associated with these beneficial effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/elsc.201600167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999383PMC

Mitochondrial Haplogroup Reveals the Genetic Basis of Diabetes Mellitus Type 2 Comorbidity in Psoriasis.

Med Princ Pract 2020 Jul 6. Epub 2020 Jul 6.

Objective: Published data has shown a clear link between psoriasis (Ps) and the increasing prevalence of comorbid conditions, such as diabetes mellitus type 2 (DM2). The mitochondrial genomic haplogroup's role in the potential coexistence of psoriasis and DM2 comorbidity is the subject of this study.

Material And Method: Ninety-eight Kuwaiti individuals were recruited in 4 cohorts (20 healthy controls (HC), 15 with DM2, 34 with psoriasis, and 29 with psoriasis and diabetes mellitus (PsDM2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000509937DOI Listing

The relationship between sleep disturbance, symptoms and daytime functioning in psoriasis: a prospective study integrating actigraphy and experience sampling methodology.

Sleep Med 2020 Mar 23;72:144-149. Epub 2020 Mar 23.

Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.

Objective/background: Sleep disturbance is common in individuals with psoriasis and appears to be related to both physical and psychological factors. We sought to examine whether psoriasis symptoms, night-time arousal and low mood predicted subsequent objective and self-reported sleep; and whether objective and self-reported sleep predicted next-day psoriasis symptoms and day-time functioning.

Participants/methods: A total of 19 individuals (Female: 11 [57. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2020.03.013DOI Listing

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages.

Exp Dermatol 2020 Jul 6. Epub 2020 Jul 6.

Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.

The skin as a neuroendocrine organ and the role of neuroendocrine signaling in the development of disorders affecting the skin and its appendages has received increasing attention in the last years. Different neuroendocrine systems have been described in the barrier organ skin, including the thyroid system, the hypothalamic-pituitary-adrenal axis, the opioid, the endocannabinoid, the cholinergic, the secosteroidogenic and the serotonergic systems. All of these systems have been implicated in the development of skin diseases, which often have an inflammatory origin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.14145DOI Listing

Role of regulatory T cells in psoriasis pathogenesis and treatment.

Br J Dermatol 2020 Jul 6. Epub 2020 Jul 6.

Medical Research Council Human Immunology Unit, Department of Medicine, Oxford National Institute for Health Research Biomedical Research Centre, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Psoriasis is a chronic inflammatory disease with a strong genetic component that can be triggered by environmental factors. Disease pathogenesis is mainly driven by type 1 and type 17 cytokine-producing cells which, in healthy individuals, are modulated by regulatory T cells (Tregs). Tregs play a fundamental role in immune homeostasis and contribute to the prevention of autoimmune disease by suppressing immune responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19380DOI Listing

Indoor salt water baths followed by artificial ultraviolet B-light for chronic plaque psoriasis: abridged Cochrane review.

Br J Dermatol 2020 Jul 6. Epub 2020 Jul 6.

Department of Dermatology, Ruhr-Universität Bochum, Bochum, Germany.

It has been suggested that indoor salt water baths with exposure to artificial UVB, may benefit patients with psoriasis. Artificial exposure to ultraviolet B-light (UVB) while soaking in an indoor salt bath, also called balneophototherapy, could simulate the natural exposure to the sun while bathing in the Dead Sea. However, the evidence underlying clinical efficacy, such as longer remission from disease and higher dermatology-related quality of life, has not yet been clearly evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19385DOI Listing

[Mechanism prediction of Simiao Yongan Decoction in treatment of psoriasis arthritis based on network pharmacology].

Authors:
Di Ma Gui-Qin Ma

Zhongguo Zhong Yao Za Zhi 2020 Jun;45(11):2611-2618

Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China.

To explore the main target and signal pathway of Simiao Yongan Decoction in the treatment of psoriatic arthritis(PsA) by network pharmacology, so as to reveal the intervention mechanism of Simiao Yongan Decoction in the treatment of psoriatic arthritis. The platform of pharmacology technology of traditional Chinese medicine system(TCMSP) was used to predict and screen the active ingredients of Simiao Yongan Decoction, and GeneCards database was searched to obtain the disease target related to the psoriatic arthritis. Protein interaction network model was constructed with STRING platform; drug-component-target-disease network map was constructed with Cytoscape Software; Wayne Diagram of common target of Simiao Yongan Decoction and psoriasis arthritis was drawn with the help of ClusterProfiler R Software. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19540/j.cnki.cjcmm.20200225.401DOI Listing

Psoriasis severity matters when dealing with all-cause mortality in psoriasis patients: a record linkage analysis in Northern Italy.

Arch Dermatol Res 2020 Jul 5. Epub 2020 Jul 5.

Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Via Clara Maffei 4, 24121, Bergamo, Italy.

Psoriasis has been linked with several comorbidities and increased all-cause mortality compared with the general population. Data are still limited concerning mortality especially from Southern European countries. Between January 2012 and December 2018, we conducted a retrospective cohort study on psoriasis patients and population controls in Northern Italy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-020-02101-1DOI Listing

Association of Serum Vitamin D With Psoriasis and Effect Modification by Central Obesity.

Front Med (Lausanne) 2020 18;7:236. Epub 2020 Jun 18.

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.

Psoriasis is a chronic recurrent inflammatory disease involving many common mechanisms associated with obesity, such as systemic inflammation and vitamin D deficiency. This study aimed to examine the association of the serum concentration of 25-hydroxyvitamin D with psoriasis and the effect modification by obesity among the affected patients. A mixed cross-section study was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2020.00236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315806PMC

Effectiveness of a stop smoking service in reducing cigarette smoking in patients referred from an NHS dermatology centre.

Br J Dermatol 2020 Jul 4. Epub 2020 Jul 4.

Department of Dermatology, University Hospital of Wales, Cardiff, UK.

Cigarette smoking is the leading avoidable cause of mortality in the UK. Individuals who start smoking in early adult life lose 10 years of life expectancy. Smoking is a risk factor for psoriasis [odds ratio (OR) of 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19378DOI Listing

Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis.

Clin Rheumatol 2020 Jul 5. Epub 2020 Jul 5.

Harvard Medical School, Boston, MA, USA.

Multiple autoinflammatory diseases, including psoriasis, psoriatic arthritis, and systemic lupus erythematosus, have been linked to increased risk of cardiovascular disease. Inflammation is known to play a key role in the pathogenesis of atherosclerosis, thus the contribution of systemic immune dysregulation, which characterizes such inflammatory conditions, towards the development of cardiovascular disease has garnered considerable interest. Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease, but risk of cardiovascular disease amongst patients with cutaneous lupus is less well known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-020-05257-3DOI Listing

Obesity, but Not Metabolic Diseases, Is Associated with Risk of Psoriasis: A Population-Based Cohort Study in Taiwan.

Dermatology 2020 Jul 3:1-8. Epub 2020 Jul 3.

Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan,

Background: Obesity and metabolic diseases including diabetes, hyperlipidemia, and hypertension are reportedly associated with an increased risk of psoriasis. However, few prospective studies have investigated the association of obesity and metabolic diseases with the risk of psoriasis.

Objective: To examine whether obesity or metabolic diseases increase the risk of psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508303DOI Listing

Anti-psoriatic effect of Lavandula angustifolia essential oil and its major components linalool and linalyl acetate.

J Ethnopharmacol 2020 Jul 2:113127. Epub 2020 Jul 2.

CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, 226015, UP, India. Electronic address:

Ethno-pharmacological Relevance: Lavender oil (LO) is an aromatic/essential oil extracted from Lavandula angustifolia and traditionally used as an aromatherapy massage oil due to its anti-inflammatory and wound healing property and also for providing the relief in other skin conditions such as psoriasis, dermatitis and eczema. However, LO has not been evaluated scientifically for psoriasis like skin inflammation.

Aim Of The Study: This study aimed to investigate the LO and its major components linalool (L) and linalyl acetate (LA) against psoriasis like skin inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2020.113127DOI Listing

The Risk of Respiratory Tract Infections in Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic.

J Am Acad Dermatol 2020 Jul 2. Epub 2020 Jul 2.

Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.06.1014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331500PMC

Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes.

J Dermatol Sci 2020 Jun 21. Epub 2020 Jun 21.

Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Kweishan, Taoyuan, Taiwan; Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan, Taiwan; Department of Anesthesiology, Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan. Electronic address:

Background: Thalidomide can be a TNF-α inhibitor for treating skin inflammation. This drug exhibits a strong toxicity that limits its application.

Objective: We synthesized a thalidomide analog containing the benzyl chloride group (2-[1-(3-chlorobenzyl)-2,6-dioxopiperidin-3-yl]isoindoline-1,3-dione, CDI) to examine anti-inflammatory activity against psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2020.05.013DOI Listing

Castleman's disease in two patients with spondyloarthritis treated by Tumor Necrosis Factor-alpha antagonists.

Joint Bone Spine 2020 Jul 1. Epub 2020 Jul 1.

Department of Rheumatology, CIC/CRB 1404, Rouen University Hospital, Normandie Univ, UNIROUEN, F 76000 Rouen, France. Electronic address:

Castleman's disease is a rare lymphoproliferative syndrome involving several anatomical and clinical entities. We report two cases of Castleman's disease in patients with spondyloarthritis (with and without psoriasis) treated with Tumor Necrosis Factor-alpha blockers. During follow-up, imaging examinations, carried out for disease assessment, fortuitously revealed a pelvic mass close to the psoas or an atypical cervical adenopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2020.06.012DOI Listing

Editorial: Psoriatic arthritis; overcoming the challenges by creating opportunities.

Clin Immunol 2020 Jul 1:108519. Epub 2020 Jul 1.

Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Sacramento, CA 95616, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2020.108519DOI Listing

Secukinumab-induced pompholyx in a psoriasis patient.

Authors:
Gerhard Eichhoff

Dermatol Online J 2020 Apr 15;26(4). Epub 2020 Apr 15.

Dermatology Service Capital and Coast District Health Board, Wellington.

With a prevalence of up to 20%, eczematous lesions are the most common skin adverse events of tumor necrosis factor alpha inhibitors. Eczematous lesions triggered by more modern biologics such as the IL17A antagonist secukinumab have been rarely reported. Herein, a case of secukinumab-induced pompholyx in a psoriasis patient is presented. Read More

View Article

Download full-text PDF

Source

Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab.

Dermatol Ther 2020 Jul 4:e13967. Epub 2020 Jul 4.

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13967DOI Listing

Management of Psychocutaneous Disorders: A Practical Approach for Dermatologists.

Dermatol Ther 2020 Jul 4:e13969. Epub 2020 Jul 4.

Division of Dermatology, Nairi Medical Clinic, Yerevan, Armenia.

Psychodermatology is a growing specialty which is gaining momentum in different parts of the world. It focuses on the connection between skin and psyche. Psychocutaneous conditions are characterized by those disorders where stress is the key element in exacerbating skin conditions or flare ups of dermatoses like psoriasis and atopic dermatitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13969DOI Listing

The effect of smoking on the psoriasis: is it related to nail involvement?

Dermatol Ther 2020 Jul 4:e13960. Epub 2020 Jul 4.

Department of Public Health, Necmettin Erbakan University Meram Medical Faculty.

Psoriasis is a chronic inflammatory skin disease that negatively affects the quality of life with remissions and relapses. Smoking, which is known to accelerate the development of comorbidities that can accompany psoriasis such as atherosclerotic heart disease, metabolic syndrome, is also an independent risk factor for psoriasis. In our study, we aimed to investigate the relationship between smoking and psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13960DOI Listing

Meningoradiculitis due to varicella zoster virus reactivation in a patient treated with ixekizumab.

Ann Dermatol Venereol 2020 Jun 30. Epub 2020 Jun 30.

Dermatology department, Jean-Bernard hospital, Valenciennes, France.

Introduction: Ixekizumab is a recently developed biopharmaceutical used since 2016 in the US and Europe for the treatment of plaque psoriasis. Few adverse effects have been reported in the literature and ixekizumab is not known to increase the risk of viral reactivation. Herein we report the case of an immunocompetent female patient treated with ixekizumab who presented meningoradiculitis due to varicella zoster virus (VZV) reactivation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2020.04.020DOI Listing

Comparison of different incremental dose regimens of narrow-band ultraviolet B in skin types III-V: a prospective, randomized, single-blind parallel study in patients with psoriasis.

J Am Acad Dermatol 2020 Jun 30. Epub 2020 Jun 30.

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China, 200443; Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China, 200072.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.06.993DOI Listing

A patient with CARD14-associated papulosquamous eruptions showing atopic dermatitis-like features.

J Eur Acad Dermatol Venereol 2020 Jul 3. Epub 2020 Jul 3.

Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Caspase recruitment domain family member 14 (CARD14) is an activator of nuclear factor kappa-light-chain-enhancer in activated B cells (NF-κB) and contributes to inflammatory responses within the epidermis. CARD14 mutations are associated with autoinflammatory keratinization diseases, such as psoriasis and familial pityriasis rubra pilaris (PRP). Recently, Craiglow et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16799DOI Listing

Psoriasis With Eczematous Features: A Retrospective Clinicopathologic Study.

Am J Dermatopathol 2020 Jun 30. Epub 2020 Jun 30.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY.

Background: Dermatopathologists sometimes encounter patients with features of psoriasis vulgaris and additional changes of eczematous dermatoses. These cases are challenging to diagnose, and the clinical implications are unclear. In the age of targeted therapy, it is important to improve our understanding of these findings so that patients are managed appropriately. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001711DOI Listing

COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy versus apremilast in North Spain.

Dermatol Ther 2020 Jul 3:e13961. Epub 2020 Jul 3.

Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Immunosuppressive and immunomodulatory treatments are critical for the management of inflammatory and autoimmune conditions such as psoriasis or psoriatic arthritis. Like in those illnesses, the lung injury and acute respiratory distress shown in COVID-19 patients are the result of a disruption in the balance of pro- and anti-inflammatory cytokines. This hyperinflammatory response to SARS-CoV-2, associated with the severity of the coronavirus disease, is called the cytokine storm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13961DOI Listing

Real life experience of guselkumab in patients with psoriasis.

Dermatol Ther 2020 Jul 3:e13964. Epub 2020 Jul 3.

Department of Dermatology, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel.

High levels of efficacy were demonstrated in randomized controlled trials assessing the efficacy of guselkumab, however real-life data is lacking. In this retrospective cohort study, we assessed the efficacy and safety of guselkumab in a cohort of psoriasis patients heavily pretreated with biologic agents. Primary efficacy endpoint was the percentage of patients achieving ≥ PASI 90 response at week 24. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13964DOI Listing

Sleep Quality in Psoriasis Patients and its Relations with Possible Affecting Factors.

Sisli Etfal Hastan Tip Bul 2020 20;54(2):181-187. Epub 2020 May 20.

Department of Neurology, Bakirkoy Prof. Dr. Mazhar Osman Research and Training Hospital for Psychiatry, Istanbul, Turkey.

Objectives: Psoriasis (PS) is a chronic, immune-mediated inflammatory skin disease. PS may lead to significant effects on health-related quality of life (HRQoL) and other outcomes. In the present study, an investigation into sleep quality (SQ), and its possible relations with factors which may affect SQ were aimed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14744/SEMB.2018.53189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326668PMC

Decreased levels of interleukin 27 in the serum of vitiligo patients.

An Bras Dermatol 2020 Jun 16. Epub 2020 Jun 16.

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:

Background: Vitiligo is a common skin disorder in which melanocytes are destroyed by auto-reactive immune responses. The loss of melanocytes results in the appearance of depigmented areas in different parts of the body. Cytokines have remarkable roles in the pathogenesis of vitiligo, such as IL-1, IL-6, and TNF-α; interleukin 27 (IL-27) is a new member of the IL-6/IL-12 family, mainly released by activated antigen-presenting cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.abd.2020.02.005DOI Listing

Biologics in the treatment of pustular psoriasis.

Expert Opin Drug Saf 2020 Jul 2:1-11. Epub 2020 Jul 2.

Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, China.

Introduction: Pustular psoriasis is a group of skin diseases characterized by neutrophil infiltration in the epidermis and formation of sterile pustules. Conventional treatments, such as retinoids and immunosuppressive drugs, have improved the clinical manifestations; however, many patients suffer from drug-related toxicity or are resistant to therapy.

Areas Covered: In this review, the authors focus on the efficacy and safety of these biologics, including anti-IL-1β (gevokizumab and canakinumab), anti-IL-1 R (anakinra), anti-IL-36 R (BI 655130), anti-tumor necrosis factor-α (etanercept, infliximab, and adalimumab), anti-IL-12/23 (ustekinumab), anti-IL-17A (secukinumab and ixekizumab), anti-IL-17RA (brodalumab), anti-IL-2 R (basiliximab), anti-IL-6 R (tocilizumab), and anti-IL-23 (risankizumab and guselkumab), for treating pustular psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2020.1785427DOI Listing

Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis.

J Pharm Biomed Anal 2020 Jun 18;189:113433. Epub 2020 Jun 18.

Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address:

Therapeutic drug monitoring, which is the measurement of drug concentrations in the blood, is a useful tool to guide clinical decision-making and treatment adjustments, on the condition that drug concentrations are correlated with treatment response. For guselkumab, an anti-IL-23 monoclonal antibody for the treatment of moderate-to-severe psoriasis, such a concentration-response relationship could not yet be determined as no commercial assays for the quantification of this drug or antibodies against this drug are available. Therefore, the aim of this study was to develop and validate immunoassays for the quantification of guselkumab and anti-guselkumab antibodies according to the guidelines of the European Medicines Agency (EMA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2020.113433DOI Listing

Characterization of PCSK9 in the Blood and Skin of Psoriasis.

J Invest Dermatol 2020 Jun 29. Epub 2020 Jun 29.

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD. Electronic address:

Mechanisms explaining the link between psoriasis, a pro-inflammatory condition, and cardiovascular disease (CVD) are not fully known. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is predominantly expressed in hepatocytes as a critical regulator of lipid metabolism and clinical trials targeting PCSK9 reduce CVD. Independent of its role in lipid metabolism, PCSK9 levels associate with endothelial dysfunction and predict CV events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.05.115DOI Listing

Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study.

Clin Ter 2020 Jul-Aug;171(4):e310-e315

Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Rome, Italy.

Background: Psoriasis is a multifactorial chronic inflammatory skin disease characterized by erythemato-squamous lesions with a chronic relapsing course. The desease clinical activity (PASI) and the patient's quality of life (DLQI) are the main elements to assess for setting up a correct therapeutic management.

Objectives: The aim of the study was to evaluate the management of the patient with moderate-severe psoriasis in therapy with biological drugs and to establish the difference in the achievement of PASI 90 and DLQI 0-1 between a group of patients treated with only biological drugs and a group of patients receiving biologic therapy in combination with a topical ointment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7417/CT.2020.2234DOI Listing

Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis.

Dermatol Ther 2020 Jul 2:e13943. Epub 2020 Jul 2.

Dermatology Unit; Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine; University of Modena and Reggio Emilia, Modena, Italy.

The therapeutic approach to patients with psoriasis and concomitant multiple sclerosis is challenging. We report the clinical case of a 44-year-old man affected by psoriasis and psoriatic arthritis treated with secukinumab for 2 years, who received also dimethyl fumarate because of a recent diagnosis of relapsing remitting multiple sclerosis. Moreover, a mini-review of the available literature regarding the use of secukinumab in patients with psoriasis or ankylosing spondylitis and coexisting central nervous system demyelinating diseases was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13943DOI Listing

Increased level of high mobility group box 1 in the serum and skin in patients with generalized pustular psoriasis.

J Dermatol 2020 Jul 1. Epub 2020 Jul 1.

Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

High-mobility group box 1 (HMGB-1) is a highly abundant pro-inflammatory protein associated with the pathogenesis of inflammatory and autoimmune diseases. HMGB-1 expression level increases in patients with psoriasis vulgaris (PV). However, HMGB-1 expression in patients with generalized pustular psoriasis (GPP) is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15467DOI Listing

Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan.

J Dermatol 2020 Jul 1. Epub 2020 Jul 1.

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

We retrospectively analyzed 66 patients with palmoplantar pustulosis (PPP) from January 1994 to September 2019 in our department. Interleukin-36 receptor antagonist gene (IL36RN) intron 3 c.115+6T>C mutation was present in two out of 27 patients (7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15470DOI Listing

Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment.

J Dermatol 2020 Jul 1. Epub 2020 Jul 1.

Department of Dermatology, Taipei Medical University- Shuang Ho Hospital, New Taipei City, Taiwan.

Immune checkpoint inhibitors, including anti-programmed death 1 and anti-programmed death ligand 1, have become prominent treatment options for various types of cancers. However, immune checkpoint inhibitors are associated with various cutaneous adverse events, one of which is psoriasiform drug eruption. Some cases of psoriasiform drug eruption can only be controlled through the cessation of immune checkpoint inhibitors and administration of systemic immunosuppressants, such as corticosteroids and methotrexate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15371DOI Listing

Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach.

Sci Rep 2020 Jul 1;10(1):10731. Epub 2020 Jul 1.

Gastroenterology Department, Marques de Valdecilla University Hospital - IDIVAL, Santander, Cantabria, Spain.

Inflammatory bowel diseases (IBD) belong to the group of immune-mediated diseases (IMIDs). The effect of associated IMIDs in the prognosis in IBD is nowadays unknown. To describe IMIDs associated to IBD patients and evaluate differences linked to the presence or absence of IMIDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67710-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330038PMC

Effects of Apigenin on RBL-2H3, RAW264.7, and HaCaT Cells: Anti-Allergic, Anti-Inflammatory, and Skin-Protective Activities.

Int J Mol Sci 2020 Jun 29;21(13). Epub 2020 Jun 29.

Department of Medicinal Biosciences, Research Institute for Biomedical & Health Science, College of Biomedical and Health Science, Konkuk University, 268 Chungwon-daero Chungju-si 27478, Korea.

Apigenin (4',5,7-trihydroxyflavone, flavonoid) is a phenolic compound that is known to reduce the risk of chronic disease owing to its low toxicity. The first study on apigenin analyzed its effect on histamine release in the 1950s. Since then, anti-mutation and antitumor properties of apigenin have been widely reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21134620DOI Listing